HUTCHMED (NASDAQ:HCM) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a report issued on Wednesday morning.

Separately, Cantor Fitzgerald reiterated an overweight rating on shares of HUTCHMED in a research note on Friday, January 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $29.70.

HUTCHMED Stock Up 1.2 %

Shares of NASDAQ HCM opened at $16.85 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.60 and a current ratio of 2.72. HUTCHMED has a 12-month low of $10.68 and a 12-month high of $20.73. The firm has a 50 day moving average of $14.85 and a 200 day moving average of $16.61.

Institutional Investors Weigh In On HUTCHMED

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP bought a new stake in shares of HUTCHMED during the first quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. increased its holdings in HUTCHMED by 353.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company’s stock valued at $65,000 after acquiring an additional 2,801 shares during the last quarter. US Bancorp DE lifted its stake in HUTCHMED by 270.9% in the 1st quarter. US Bancorp DE now owns 3,687 shares of the company’s stock worth $70,000 after purchasing an additional 2,693 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of HUTCHMED by 28.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,723 shares of the company’s stock valued at $97,000 after purchasing an additional 1,279 shares during the last quarter. Finally, National Pension Service boosted its holdings in shares of HUTCHMED by 429.1% during the 2nd quarter. National Pension Service now owns 9,101 shares of the company’s stock valued at $115,000 after purchasing an additional 7,381 shares during the last quarter. 8.82% of the stock is owned by institutional investors.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.